Home
>
National Drug Code (NDC)
>
Cytarabine
Cytarabine - 0069-0155-01 - (Cytarabine)
Drug Information of Cytarabine
| Product NDC: | 0069-0155 |
| Proprietary Name: | Cytarabine |
| Non Proprietary Name: | Cytarabine |
| Active Ingredient(s): | 2 g/20mL & nbsp; Cytarabine |
| Administration Route(s): | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
| Dosage Form(s): | INJECTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Cytarabine
| Product NDC: | 0069-0155 |
| Labeler Name: | Pfizer Laboratories Div Pfizer Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA201784 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120131 |
Package Information of Cytarabine
| Package NDC: | 0069-0155-01 |
| Package Description: | 20 mL in 1 VIAL (0069-0155-01) |
NDC Information of Cytarabine
| NDC Code | 0069-0155-01 |
| Proprietary Name | Cytarabine |
| Package Description | 20 mL in 1 VIAL (0069-0155-01) |
| Product NDC | 0069-0155 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Cytarabine |
| Dosage Form Name | INJECTION |
| Route Name | INTRATHECAL; INTRAVENOUS; SUBCUTANEOUS |
| Start Marketing Date | 20120131 |
| Marketing Category Name | ANDA |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc. |
| Substance Name | CYTARABINE |
| Strength Number | 2 |
| Strength Unit | g/20mL |
| Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |
